| |
|
Product Name:
|
Monoclonal Anti-Influenza Virus H5 Hemagglutinin (HA) Protein (VN04-2), A/Vietnam/1203/2004 (H5N1) (ascites, Mouse)
|
|
Ownership statement:
|
This reagent is the property of the U.S. Government.
|
|
Manufacturer:
|
Rockland Immunochemicals Inc.
|
|
Material Provided:
|
Each vial of NR-2730 contains lyophilized (1.0 mL) mouse ascites fluid. Sodium azide (0.02%) and gentamycin (0.01%) were added to NR-2730, lot 7497746.
|
|
Packing/Storage:
|
NR-2730 was packaged in glass serum vials with an aluminum crimp seal. The product is provided frozen and should be stored at -20°C to -40°C immediately upon arrival. Storage at warmer temperatures is not recommended due to a low bioburden. At colder temperatures, the rubber stopper may become brittle and compromise the seal. NR-2730 should be reconstituted with 1.0 mL of sterile distilled water. Reconstituted material should be stored at -20°C to -40°C. Reconstituted material may be thawed at room temperature and should be re-frozen.
|
|
Functional Activity:
|
NR-2730 is specific for the H5 HA subtype of the influenza A virus as determined in standard hemagglutination inhibition (HI) assays. NR-2730 also demonstrates high reactivity within the H5 HA subtype of Asian isolates of influenza A virus, based on HI assays.
Applications: HI, ELISA, immunocytochemistry, immunoprecipitation, virus neutralization test.
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Guan, Y., et al. “H5N1 Influenza: A Protean Pandemic Threat.” Proc. Natl. Acad. Sci. USA 101 (2004): 8156– 8161. PubMed: 15148370.
2. Li, K. S., et al. “Genesis of a Highly Pathogenic and Potentially Pandemic H5N1 Influenza Virus in Eastern Asia.” Nature 430 (2004): 209–213. PubMed: 15241415. GenPept: AAT73274.
3. Mueller, U. W., C. S. Hawes, and W. R. Jones. “Monoclonal Antibody Production by Hybridoma Growth in Freund’s Adjuvant Primed Mice.” J. Immunol. Methods 87 (1986): 193–196. PubMed: 3950429.
4. Skehel, J. J. and D. C. Wiley. “Receptor Binding and Membrane Fusion in Virus Entry: The Influenza Hemagglutinin.” Annu. Rev. Biochem. 69 (2000): 531– 569. PubMed: 10966468.
5. Stevens, J., et al. “Structure and Receptor Specificity of the Hemagglutinin from an H5N1 Influenza Virus.” Science 312 (2006): 404–410. PubMed: 16543414.
6. Hatta, M., P. Gao, P. Halfmann, and Y. Kawaoka. “Molecular Basis for High Virulence of Hong Kong H5N1 Influenza A Viruses.” Science 293 (2001): 1840–1842. PubMed: 11546875.
7. Hoffmann, E., et al. “Role of Specific Hemagglutinin Amino Acids in the Immunogenicity and Protection of H5N1 Influenza Virus Vaccines.” Proc. Natl. Acad. Sci. USA 102 (2005): 12915–12920. PubMed: 16118277.
8. Govorkova, E. A., et al. “Immunization with Reverse-Genetics-Produced H5N1 Influenza Vaccine Protects Ferrets Against Homologous and Heterologous Challenge.” J. Infect. Dis. 194 (2006): 159–167. PubMed: 16779721.
|
|
Citation:
|
Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-Influenza Virus H5 Hemagglutinin (HA) Protein (VN04-2), A/Vietnam/1203/2004 (H5N1), (ascites, Mouse), NR-2730."
|
|
Biosafety Level:
|
1
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|